Welcome to SWEBAGS

The Swedish Basal Ganglia Society, SWEBAGS, is an non-profit scientific organization providing a platform for discussions and education opportunities in the area of basal ganglia research.

We aim to increase the visibility of mainly basic and pre-clinical research, and foster multidisciplinary collaborations across biological scales and methodological approaches. All professionals, students and organisations interested in basal ganglia research are welcome to become members.

Together we will leverage the strengths of basal ganglia research in Sweden, join us in our efforts and participate in our activities!

– Jeanette Hellgren Kotaleski, Professor, KTH Royal Institute of technology, Chair SWEBAGS
– Angela Cenci Nilsson, Professor, Lund University, Vice Chair SWEBAGS

Latest News:

  • New publication: Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.

    Author: Espa E, Song L, Skovgård K, Fanni S, Cenci MA.


    Background: Current models of L-DOPA-induced dyskinesia (LID) are obtained by treating dopamine-depleted animals with L-DOPA. However, patients with LID receive combination therapies that often include dopamine agonists. 

    Objective: Using 6-hydroxydopamine-lesioned rats as a model, we aimed to establish whether adjunct treatment with the D2/3 agonist ropinirole impacts on patterns of LID-related neuroplasticity and drug responses. 

    Methods: Different regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment were compared using measures of hypokinesia and dyskinesia. Striatal expression of ∆FosB and angiogenesis markers were studied immunohistochemically. Antidyskinetic effects of different drug categories were investigated in parallel groups of rats receiving either L-DOPA monotreatment or L-DOPA combined with ropinirole.

    Results: We defined chronic regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment inducing overall similar abnormal involuntary movement scores. Compared to the monotreatment group, animals receiving the L-DOPA-ropinirole combination exhibited an overall lower striatal expression of ∆FosB with a distinctive compartmental distribution. The expression of angiogenesis markers and blood-brain barrier hyperpermeability was markedly reduced following L-DOPA-ropinirole cotreatment vs L-DOPA monotreatment. Significant group differences were moreover detected upon comparing the response to candidate antidyskinetic drugs. In particular, compounds modulating D1 receptor signaling had a stronger effect in the L-DOPA-only group, whereas both amantadine and the selective NMDA antagonist MK801 produced a markedly larger antidyskinetic effect in L-DOPA-ropinirole cotreated animals.

    Conclusions: Cotreatment with ropinirole altered LID-related neuroplasticity and pharmacological response profiles. The impact of adjuvant dopamine agonist treatment should be taken into consideration when investigating LID mechanisms candidate interventions in both clinical and experimental settings. 

    Link: https://pubmed.ncbi.nlm.nih.gov/36656044/

  • IBAGS 2023

    The abstract submission deadline and early-bird registration time has been prolonged to January 31st 2023.

More news …